$RDC (-1,66%)
- Total sales +32% to EUR 2.4 bn in FY 2024 (Q4, +27%), with DACH +33% (Q4, 27%) and International +26% (Q4, 29%). Non-Rx sales +21% to EUR 1.6 bn (Q4, +22%).
- Record gain in active customers, up 1.7M to 12.5M, with German Rx customer base more than doubling.
- Now market leader in Italy, after already being number 1 in Austria, Belgium, Switzerland and Germany.
- Full-year adj. EBITDA EUR 33M, 1.4% margin (Q4, -0.7%). In Q4, elevated levels of e-Rx marketing and some head wind from no peak in cold and flu.
- DACH adj. EBITDA margin 2.6%; International improved 2.4pp to -3.8%.
- Full-year guidance for 2025: Total sales to grow in excess of 25%, Rx in Germany in excess of EUR 0.5bn, total Group non-Rx sales growth in excess of 18%, adj. EBITDA margin at a positive 2% to 2.5% for the full year.
Quelle: https://ir.redcare-pharmacy.com/en/news/building-on-a-successful-2024-redcare-pharmacy-expects-margin-uplift-and-unabated-fast-growth-in/6e4dd580-517d-4797-a320-048c73c298eb
